Clinical Trial Update: Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating LDE225 (sonidegib) in combination with bortezomib for relapsed or relapsed/refractory multiple myeloma was terminated, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• LDE225 (sonidegib) (sonidegib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2017-02-16